AAPL333.02+11.36 (+3.53%) ▲|ABBV259.36+2.44 (+0.95%) ▲|ABT103.06+2.31 (+2.29%) ▲|ACN146.99+8.25 (+5.95%) ▲|ADBE225.11+12.94 (+6.10%) ▲|AMAT536.25-26.55 (-4.72%) ▼|AMD521.95-17.74 (-3.29%) ▼|AMGN376.04+4.54 (+1.22%) ▲|AMT166.67+2.02 (+1.23%) ▲|AMZN232.11-1.55 (-0.66%) ▼|AVGO381.92-10.55 (-2.69%) ▼|AXP326.17-14.67 (-4.30%) ▼|BA209.52+0.29 (+0.14%) ▲|BAC62.05+0.77 (+1.26%) ▲|BKNG177.46+4.63 (+2.68%) ▲|BLK1,055.67+18.51 (+1.78%) ▲|BMY62.09+0.58 (+0.94%) ▲|BNY158.91-1.20 (-0.75%) ▼|BRK-B494.93+4.08 (+0.83%) ▲|C132.19+0.31 (+0.24%) ▲|CAT888.73-5.81 (-0.65%) ▼|CL90.75+0.67 (+0.74%) ▲|CMCSA22.30+0.38 (+1.71%) ▲|COF202.84+2.88 (+1.44%) ▲|COP120.26+0.06 (+0.05%) ▲|COST935.03+8.97 (+0.97%) ▲|CRM163.66+6.73 (+4.29%) ▲|CSCO114.17+1.41 (+1.25%) ▲|CVS107.74+0.85 (+0.80%) ▲|CVX194.79+0.37 (+0.19%) ▲|DE628.16+18.14 (+2.97%) ▲|DHR191.50-1.00 (-0.52%) ▼|DIS94.85+2.02 (+2.18%) ▲|DUK130.52+1.26 (+0.97%) ▲|EMR147.94+3.04 (+2.10%) ▲|FDX314.96-0.66 (-0.21%) ▼|GD386.75+4.96 (+1.30%) ▲|GE353.73+4.73 (+1.36%) ▲|GEV1,014.75-16.44 (-1.59%) ▼|GILD129.31-1.55 (-1.18%) ▼|GM82.64+1.97 (+2.44%) ▲|GOOG319.09+0.75 (+0.24%) ▲|GOOGL319.74+2.05 (+0.65%) ▲|GS1,061.23-13.49 (-1.26%) ▼|HD332.98+8.27 (+2.55%) ▲|HON243.15-3.12 (-1.27%) ▼|IBM214.19+7.54 (+3.65%) ▲|INTC92.32-7.91 (-7.89%) ▼|INTU296.33+14.80 (+5.26%) ▲|ISRG337.50+5.48 (+1.65%) ▲|JNJ263.40+4.13 (+1.59%) ▲|JPM353.21+3.31 (+0.95%) ▲|KO82.25+1.08 (+1.33%) ▲|LIN512.28+5.96 (+1.18%) ▲|LLY1,196.03+10.16 (+0.86%) ▲|LMT582.60+14.01 (+2.46%) ▲|LOW207.64+5.72 (+2.83%) ▲|LRCX305.21-14.57 (-4.56%) ▼|MA539.66+9.37 (+1.77%) ▲|MCD264.76+1.96 (+0.75%) ▲|MDLZ60.52+0.47 (+0.78%) ▲|MDT83.21+1.20 (+1.46%) ▲|META595.19-10.91 (-1.80%) ▼|MMM172.62+3.03 (+1.79%) ▲|MO72.99+0.91 (+1.26%) ▲|MRK131.07+0.59 (+0.45%) ▲|MS214.48-0.70 (-0.33%) ▼|MSFT381.70+0.12 (+0.03%) ▲|MU920.95-69.26 (-6.99%) ▼|NEE89.78-0.01 (-0.01%) ▼|NFLX70.09+1.20 (+1.74%) ▲|NKE41.70+0.71 (+1.73%) ▲|NOW98.78+6.84 (+7.44%) ▲|NVDA206.84-1.92 (-0.92%) ▼|ORCL114.99-5.05 (-4.21%) ▼|PEP136.64+1.69 (+1.25%) ▲|PFE24.54-0.04 (-0.16%) ▼|PG147.41+1.53 (+1.05%) ▲|PLTR122.92-0.45 (-0.36%) ▼|PM193.00+1.88 (+0.98%) ▲|QCOM166.97-4.14 (-2.42%) ▼|RTX212.79+3.63 (+1.74%) ▲|SBUX103.25+0.04 (+0.04%) ▲|SCHW101.97+0.36 (+0.35%) ▲|SO97.25+0.65 (+0.67%) ▲|SPG229.78+4.58 (+2.03%) ▲|T24.13+1.17 (+5.10%) ▲|TMO568.26-4.06 (-0.71%) ▼|TMUS180.09+9.67 (+5.67%) ▲|TSLA313.03-6.66 (-2.08%) ▼|TXN279.58-5.41 (-1.90%) ▼|UBER65.94-2.97 (-4.31%) ▼|UNH420.74-2.82 (-0.67%) ▼|UNP307.32+2.99 (+0.98%) ▲|UPS114.79+0.69 (+0.60%) ▲|USB63.97+0.64 (+1.01%) ▲|V355.74+4.14 (+1.18%) ▲|VZ46.38+2.56 (+5.84%) ▲|WFC86.31+0.12 (+0.14%) ▲|WMT109.47+1.07 (+0.99%) ▲|XOM156.94+0.05 (+0.03%) ▲|AAPL333.02+11.36 (+3.53%) ▲|ABBV259.36+2.44 (+0.95%) ▲|ABT103.06+2.31 (+2.29%) ▲|ACN146.99+8.25 (+5.95%) ▲|ADBE225.11+12.94 (+6.10%) ▲|AMAT536.25-26.55 (-4.72%) ▼|AMD521.95-17.74 (-3.29%) ▼|AMGN376.04+4.54 (+1.22%) ▲|AMT166.67+2.02 (+1.23%) ▲|AMZN232.11-1.55 (-0.66%) ▼|AVGO381.92-10.55 (-2.69%) ▼|AXP326.17-14.67 (-4.30%) ▼|BA209.52+0.29 (+0.14%) ▲|BAC62.05+0.77 (+1.26%) ▲|BKNG177.46+4.63 (+2.68%) ▲|BLK1,055.67+18.51 (+1.78%) ▲|BMY62.09+0.58 (+0.94%) ▲|BNY158.91-1.20 (-0.75%) ▼|BRK-B494.93+4.08 (+0.83%) ▲|C132.19+0.31 (+0.24%) ▲|CAT888.73-5.81 (-0.65%) ▼|CL90.75+0.67 (+0.74%) ▲|CMCSA22.30+0.38 (+1.71%) ▲|COF202.84+2.88 (+1.44%) ▲|COP120.26+0.06 (+0.05%) ▲|COST935.03+8.97 (+0.97%) ▲|CRM163.66+6.73 (+4.29%) ▲|CSCO114.17+1.41 (+1.25%) ▲|CVS107.74+0.85 (+0.80%) ▲|CVX194.79+0.37 (+0.19%) ▲|DE628.16+18.14 (+2.97%) ▲|DHR191.50-1.00 (-0.52%) ▼|DIS94.85+2.02 (+2.18%) ▲|DUK130.52+1.26 (+0.97%) ▲|EMR147.94+3.04 (+2.10%) ▲|FDX314.96-0.66 (-0.21%) ▼|GD386.75+4.96 (+1.30%) ▲|GE353.73+4.73 (+1.36%) ▲|GEV1,014.75-16.44 (-1.59%) ▼|GILD129.31-1.55 (-1.18%) ▼|GM82.64+1.97 (+2.44%) ▲|GOOG319.09+0.75 (+0.24%) ▲|GOOGL319.74+2.05 (+0.65%) ▲|GS1,061.23-13.49 (-1.26%) ▼|HD332.98+8.27 (+2.55%) ▲|HON243.15-3.12 (-1.27%) ▼|IBM214.19+7.54 (+3.65%) ▲|INTC92.32-7.91 (-7.89%) ▼|INTU296.33+14.80 (+5.26%) ▲|ISRG337.50+5.48 (+1.65%) ▲|JNJ263.40+4.13 (+1.59%) ▲|JPM353.21+3.31 (+0.95%) ▲|KO82.25+1.08 (+1.33%) ▲|LIN512.28+5.96 (+1.18%) ▲|LLY1,196.03+10.16 (+0.86%) ▲|LMT582.60+14.01 (+2.46%) ▲|LOW207.64+5.72 (+2.83%) ▲|LRCX305.21-14.57 (-4.56%) ▼|MA539.66+9.37 (+1.77%) ▲|MCD264.76+1.96 (+0.75%) ▲|MDLZ60.52+0.47 (+0.78%) ▲|MDT83.21+1.20 (+1.46%) ▲|META595.19-10.91 (-1.80%) ▼|MMM172.62+3.03 (+1.79%) ▲|MO72.99+0.91 (+1.26%) ▲|MRK131.07+0.59 (+0.45%) ▲|MS214.48-0.70 (-0.33%) ▼|MSFT381.70+0.12 (+0.03%) ▲|MU920.95-69.26 (-6.99%) ▼|NEE89.78-0.01 (-0.01%) ▼|NFLX70.09+1.20 (+1.74%) ▲|NKE41.70+0.71 (+1.73%) ▲|NOW98.78+6.84 (+7.44%) ▲|NVDA206.84-1.92 (-0.92%) ▼|ORCL114.99-5.05 (-4.21%) ▼|PEP136.64+1.69 (+1.25%) ▲|PFE24.54-0.04 (-0.16%) ▼|PG147.41+1.53 (+1.05%) ▲|PLTR122.92-0.45 (-0.36%) ▼|PM193.00+1.88 (+0.98%) ▲|QCOM166.97-4.14 (-2.42%) ▼|RTX212.79+3.63 (+1.74%) ▲|SBUX103.25+0.04 (+0.04%) ▲|SCHW101.97+0.36 (+0.35%) ▲|SO97.25+0.65 (+0.67%) ▲|SPG229.78+4.58 (+2.03%) ▲|T24.13+1.17 (+5.10%) ▲|TMO568.26-4.06 (-0.71%) ▼|TMUS180.09+9.67 (+5.67%) ▲|TSLA313.03-6.66 (-2.08%) ▼|TXN279.58-5.41 (-1.90%) ▼|UBER65.94-2.97 (-4.31%) ▼|UNH420.74-2.82 (-0.67%) ▼|UNP307.32+2.99 (+0.98%) ▲|UPS114.79+0.69 (+0.60%) ▲|USB63.97+0.64 (+1.01%) ▲|V355.74+4.14 (+1.18%) ▲|VZ46.38+2.56 (+5.84%) ▲|WFC86.31+0.12 (+0.14%) ▲|WMT109.47+1.07 (+0.99%) ▲|XOM156.94+0.05 (+0.03%) ▲|
21.4 C
New York
Sunday, July 26, 2026

Tag: cancer treatment

newssourceFORcompanyinformationcontent1releasesmarket

Osara Health Expands Into Survivorship Care, Strengthening Cancer Support Beyond Treatment

The expanded Cancer Coach program introduces new survivorship modules building on the latest outcomes showing a 25:1 ROI and ~66% of participants improved physical...

Booking Health Announces Release of Findings on International Access to Personalized Glioblastoma Treatment in Germany

Langenfeld, Germany, June 03, 2026 (GLOBE NEWSWIRE) -- Booking Health today announced the release of findings examining international patient access to personalized dendritic cell therapy for glioblastoma in Germany. The findings, based on a documented Canadian patient case and supporting clinical research, highlight how cross-border treatment pathways may provide patients with aggressive brain tumors access to individualized immunotherapy options that are not widely available within all healthcare systems.

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

   
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial

Caris Life Sciences Demonstrates Scientific Rigor with Clinical Validation of FDA-Approved MI Cancer Seek®

IRVING, Texas, Aug. 15, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published...

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

2H 2025 is shaping up to be a defining year for LIXTE (Nasdaq: LIXT) and its lead compound LB-100

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

Pediatric Relapsed/Refractory Neuroblastoma Market is on an Upward Trend, Driven by Innovation and Unmet Need | DelveInsight

The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...

HopeAI Joins Mayo Clinic Platform to Transform the Future of Drug Development with AI

NEW YORK, Aug. 12, 2025 /PRNewswire/ -- HopeAI, an emerging leader in applying artificial intelligence (AI) to accelerate new drug development, has officially joined...

5 Pew-Stewart Scholars Selected to Pursue Pioneering Cancer Research

PHILADELPHIA, Aug. 12, 2025 /PRNewswire/ -- The Pew Charitable Trusts and the Alexander and Margaret Stewart Trust announced today the 2025 class of the...

Booking Health Unveils New Study: Role of Immunotherapy in Extending Life Expectancy for Stage4 Cervical Cancer Patients

Langenfeld, Germany, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Booking Health, a global leader in medical treatment coordination, today unveiled a new study titled Role of Immunotherapy in Extending Life Expectancy for Stage 4 Cervical Cancer Patients. The report outlines how cutting-edge immunotherapy is reshaping care for women with advanced cervical cancer, offering new pathways to longer survival and improved quality of life, particularly in cases resistant to standard treatments.

Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy

HONG KONG, Aug. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter,...

US NCI Sponsors Senhwa Biosciences’ Second Program-IND Submitted for Clinical Trial Targeting MYC-Aberrant Lymphoma

TAIPEI and SAN DIEGO, Aug. 7, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for...

Everhope Oncology Launches First Cancer Daycare Centre in Gurugram — Revolutionizing Cancer Care with Compassion, Precision and Convenience

Everhope Oncology takes the anxiety out of cancer treatment — with zero wait time, 2X faster service, pre-booked diagnostics, and personalised concierge-led assistance. GURUGRAM, India,...

Medical College of Wisconsin Celebrates Grand Opening of the Center for Cancer Discovery, Heralding a New Era of Cancer Research in Wisconsin

MILWAUKEE, Aug. 5, 2025 /PRNewswire/ -- Today, the Medical College of Wisconsin (MCW) hosted a ribbon cutting ceremony to celebrate the grand opening of...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCancer treatment

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers